These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells. Silva LM; Jacobs DT; Allard BA; Fields TA; Sharma M; Wallace DP; Tran PV Sci Rep; 2018 Mar; 8(1):4985. PubMed ID: 29563577 [TBL] [Abstract][Full Text] [Related]
28. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression. Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180 [TBL] [Abstract][Full Text] [Related]
35. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model. Zhu Y; Teng T; Wang H; Guo H; Du L; Yang B; Yin X; Sun Y Food Funct; 2018 Jan; 9(1):389-396. PubMed ID: 29215110 [TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Liu C; Zhang Y; Yuan L; Fu L; Mei C Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113 [TBL] [Abstract][Full Text] [Related]
37. Notch3 as a novel therapeutic target for the treatment of ADPKD by regulating cell proliferation and renal cyst development. Su L; Chen T; Hu H; Xu Z; Luan X; Fu K; Ren Y; Sun D; Sun Y; Guo D Biochem Pharmacol; 2024 Jun; 224():116200. PubMed ID: 38604258 [TBL] [Abstract][Full Text] [Related]
38. Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth in Yang Y; Chen M; Zhou J; Lv J; Song S; Fu L; Chen J; Yang M; Mei C J Am Soc Nephrol; 2018 Sep; 29(9):2310-2325. PubMed ID: 30042193 [TBL] [Abstract][Full Text] [Related]
39. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). Nikonova AS; Deneka AY; Kiseleva AA; Korobeynikov V; Gaponova A; Serebriiskii IG; Kopp MC; Hensley HH; Seeger-Nukpezah TN; Somlo S; Proia DA; Golemis EA FASEB J; 2018 May; 32(5):2735-2746. PubMed ID: 29401581 [TBL] [Abstract][Full Text] [Related]
40. Modulation of polycystic kidney disease by non-coding RNAs. Ramalingam H; Yheskel M; Patel V Cell Signal; 2020 Jul; 71():109548. PubMed ID: 31982550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]